Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study
This study provides valuable insights into the characteristics of late-onset immune-related adverse events. To further advance our understanding of these late-onset toxicities, dedicated prospective studies are needed to assess risk factors associated with their development and their impact on quality of life. Additionally, translational research focused on finding predictive biomarkers is essential to identify patients at a higher risk of developing delayed adverse events and to understand how best to manage them.
Authors
- Priya Ganesan
- L.H. Cossar
- Javier Pozas (ORCID: https://orcid.org/0000-0002-9776-9021)
- Aislinn Macklin-Doherty (ORCID: https://orcid.org/0000-0002-9665-6316)
- Sowmya Cheruvu
- Anna Claire Olsson-Brown (ORCID: https://orcid.org/0000-0001-7721-5817)
- James F. Jones (ORCID: https://orcid.org/0000-0002-1997-4257)
- James Larkin (ORCID: https://orcid.org/0000-0001-5569-9523)
- N. Garbutt
- Kate Young (ORCID: https://orcid.org/0000-0002-9500-2046)
- Alexandra Johnson (ORCID: https://orcid.org/0000-0003-0997-0372)
- Rebecca Lee (ORCID: https://orcid.org/0000-0003-2540-2009)
- Arjun Modi
- Poorni Priya Jaganathan
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- Royal Marsden Hospital (GB)
- The Christie NHS Foundation Trust (GB)
- University College London (GB)
Publication Details
- Journal
- Cancers
- Published
- 2025-07-25
- DOI
- https://doi.org/10.3390/cancers17152461
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Institute for Health and Care Research
- Department of Health and Social Care